oxodotreotide

Oxodotreotide (also known as dotatate) is a somatostatin analog that serves as a targeting ligand in radiopharmaceutical therapy. When chelated with the beta-emitting radioisotope lutetium-177, it forms **lutetium (177Lu) oxodotreotide**, a peptide receptor radionuclide therapy (PRRT). The drug exhibits high affinity for somatostatin receptors (SSTRs), particularly the SSTR2 subtype, which is frequently overexpressed in neuroendocrine neoplasms (NENs). Upon binding to these receptors, the complex is internalized into the tumor cell, where the lutetium-177 isotope delivers localized ionizing radiation, causing double-stranded DNA breaks and subsequent cell death. Beijing Xiantong International Pharmaceutical is developing a version of this agent in China (XT001) for the treatment of somatostatin receptor-positive advanced neuroendocrine neoplasms, including those that are non-grade 1/2 gastroenteropancreatic neuroendocrine tumors.

Brand names

Lutathera

Other names

dotatateDOTA-TATEDOTA-D-Phe1-Tyr3-octreotateDOTA-D-Phe-1-Tyr3-octreotateDOTA-D-Phe 1-Tyr3-octreotatelutetium (177Lu) oxodotreotide[177Lu]Lu-DOTA-TATE